Who are Vinflunine plus Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEDAZURIDINE, Dacogen, Vidaza, Zymar, Eloxatin, Hepsera.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vinflunine-plus-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vinflunine plus Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vinflunine plus Capecitabine (Vinflunine plus Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapeutic agent and fluoropyrimidine. Area: Oncology.

phase 3 Platinum-based chemotherapeutic agent and fluoropyrimidine DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Vinflunine plus Capecitabine (Vinflunine plus Capecitabine) — Pierre Fabre Medicament. Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vinflunine plus Capecitabine TARGET	Vinflunine plus Capecitabine	Pierre Fabre Medicament	phase 3	Platinum-based chemotherapeutic agent and fluoropyrimidine	DNA
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-05-14 — Vidaza · 12053482 · Method of Use · US
2029-05-14 — Vidaza · 11571436 · Formulation · US
2030-06-03 — Vidaza · 8846628 · Formulation · US

Sponsor landscape (Platinum-based chemotherapeutic agent and fluoropyrimidine class)

Pierre Fabre Medicament · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vinflunine plus Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/vinflunine-plus-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab